Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity
 of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or
 metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment
 in the advanced disease setting.
Inclusion Criteria:

 -  Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.

 -  Tumors over-expressing Her-2

 -  Candidate for treatment with docetaxel/trastuzumab

 Exclusion Criteria:

 -  Histology of inflammatory carcinoma

 -  AST and/or ALT >1.5 x ULN concomitant with ALP >2.5 x ULN